These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 28657381

  • 1. Safety profile of biological therapies for treating rheumatoid arthritis.
    Cañete JD, Hernández MV, Sanmartí R.
    Expert Opin Biol Ther; 2017 Sep; 17(9):1089-1103. PubMed ID: 28657381
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC.
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 6. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 9. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV, Sanmartí R, Cañete JD.
    Expert Opin Drug Saf; 2016 May 24; 15(5):613-24. PubMed ID: 26927029
    [Abstract] [Full Text] [Related]

  • 10. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 19; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
    Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE, French Society of Rheumatology.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):134-139. PubMed ID: 29069471
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.
    Arthritis Res Ther; 2016 Dec 01; 18(1):280. PubMed ID: 27906048
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 Dec 01; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
    Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R.
    Clin Rheumatol; 2017 Apr 01; 36(4):753-761. PubMed ID: 28058538
    [Abstract] [Full Text] [Related]

  • 18. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept.
    Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, Wendling D, Pham T, Gottenberg JE, Mariette X, Morel J, French Society of Rheumatology and the investigators participating in AIR-PR, ORA and REGATE registries.
    Rheumatology (Oxford); 2022 Mar 02; 61(3):953-962. PubMed ID: 33993216
    [Abstract] [Full Text] [Related]

  • 19. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG, den Broeder AA.
    Best Pract Res Clin Rheumatol; 2015 Mar 02; 29(4-5):543-9. PubMed ID: 26697765
    [Abstract] [Full Text] [Related]

  • 20. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D, Tavares-Costa J, Eusébio M, Leite Silva J, Ramos Rodrigues J, Sousa-Neves J, Duarte AC, Lopes C, Valido A, Dinis J, Freitas J, Santiago M, Ferreira R, Ganhão S, Miranda L, Peixoto D, Teixeira F, Alcino S, Afonso C, Santos MJ.
    Acta Reumatol Port; 2019 Mar 02; 44(2):103-113. PubMed ID: 31243259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.